Germany's Merck & Stelis Biopharma open bioprocess scale-up lab in India

“Both Merck and Stelis bring technological expertise and an extensive bioprocess development and manufacturing portfolio that will help customers accelerate development of biopharmaceuticals for clinical trials and manufacturing with greater reliability and cost effectiveness,” said Udit Batra, member of the Merck executive board and CEO, Life Science.

The collaboration reinforces Merck’s position as the premier supplier of process development and clinical state manufacturing solutions, materials and services needed for biologics production.

“In the biopharma space, where the process is the product, our process scale-up lab fulfils a critical need by offering clients a reliable process bridge between R&D and commercial scales. The collaboration with Merck completes the value proposition for CDMO customers by providing an end-to-end solution from process development and scale-up through to manufacturing for pre-clinical, clinical and commercial supply,” said Joe Thomas, CEO of Stelis Biopharma.

The lab is a center of excellence for process scale-up and manufacturing services. The collaboration brings together Stelis’ end-to-end capabilities in high-yield bioprocess development from cell line to commercial manufacturing scale and Merck’s industry leading technological expertise in bioprocessing.

The process scale-up lab and a soon-to-be-completed cGMP manufacturing facility will house Merck’s portfolio of Mobius bioprocessing equipment and single-use manufacturing components. Merck will provide process know-how and application knowledge to help establish the single-use platform technologies at Stelis as part of the collaboration.

Stelis Biopharma Pvt Ltd is a vertically integrated biopharmaceutical company with R&D, process scale-up and end-to-end manufacturing capabilities from drug substance to finished drug products in all injectable formats. Stelis has a 30,000 square feet state of the art research facility in Bengaluru along with a soon-to-be commissioned 200,000 square feet integrated bio-manufacturing facility catering to biologic APIs and aseptically filled injectables conforming to international standards. The principal shareholders of Stelis are Strides Pharma, Tenshi Life Sciences Private Limited and GMS Holdings.